Market Analysis
The Ventilator-Associated Pneumonia Market is expected to reach USD 1.1 billion by 2032, growing at a 10.2% CAGR between 2023 and 2032. Ventilator-associated pneumonia or VAP is a kind of lung infection which affects people that are on ventilators. This is caused due to trauma, neurological diseases, and lung diseases.
Various factors are adding to the global ventilator-associated pneumonia market growth. Such factors, according to the new MRFR report, include increasing expenditure on RD to develop an effective treatment for ventilator-associated pneumonia, rising cases of traumatic brain injury, and increasing prevalence of ventilator-associated pneumonia.
On the contrary, inappropriate reimbursement scenarios, high ventilator charges, and expensive diagnostic tests are factors that may limit the ventilator-associated pneumonia market growth over the forecast period.
Covid-19 Analysis/Covid-19 Impact on Ventilator-Associated Pneumonia Market
A medical ventilator is a major device which is largely being used to treat COVID-19. Following the demand for such ventilators in a mushrooming rate is forcing manufacturers to increase their production by about 50%. Several key players are giving their best in manufacturing as well as delivering innumerable ventilators possible across the globe. The surging use of medical ventilators in healthcare centers is boosting the chances of treating ventilator-associated pneumonia patients. More than 76% of the population had been diagnosed with novel coronavirus in China in February 2020. The United States is a major country where COVID-19 has cast its shadow owing to which there has been a burgeoning demand for medical ventilators all over the country. The US, according to Wall Streets, has invested above USD 2.5 billion in medical ventilators. The number of COVID-19 infected patients in India is increasing at an alarming rate. About 40% of patients have suffered from symptoms that are similar to pneumonia.
Market Segmentation
The MRFR report offers an inclusive segmental analysis of the ventilator-associated pneumonia market outlook based on end users and diagnosis.
By diagnosis, the ventilator-associated pneumonia market is segmented into microbiological, radiological, clinical, and others. The microbiological segment is further segmented into non-quantitative or semi-quantitative airway sampling, blood and pleural fluid cultures, and quantitative cultures of airway specimens.
By end user, the ventilator-associated pneumonia market is segmented into research and academic institutes, hospitals and clinics, ambulatory care centers, and others.
Regional Analysis
Based on the region, the global ventilator-associated pneumonia market report covers the recent trends growth opportunities across Europe, the Asia Pacific (APAC), the Americas, and the Middle East and Africa (MEA). Among these, the Americas will spearhead the market over the forecast period for the increasing initiatives by non-government and government organizations for controlling the disease growth and rising prevalence of ventilator-associated pneumonia.
The global ventilator-associated pneumonia market in Europe is predicted to hold the second-largest share over the forecast period for the presence of well-developed healthcare industry and huge patient population having lung diseases.
The global ventilator-associated pneumonia market in the APAC region is predicted to grow at the fastest pace over the forecast period. The rising prevalence of ventilator-associated pneumonia and increasing initiatives undertaken by the non-government and government organizations for creating awareness are adding market growth.
The global ventilator-associated pneumonia market in the MEA is predicted to have the smallest share over the forecast period for increasing cases of infectious diseases and increasing government initiatives for the development of the healthcare industry.
Key Players
Eminent players profiled in the global ventilator-associated pneumonia market report include Cardeas Pharma (US), Shionogi Inc. (Japan), Wockhardt (India), Bayer AG (Germany), Thermo Fisher Scientific (US), Nabriva Therapeutics AG (Ireland), MedImmune (US), AstraZeneca (UK), Merck Co., Inc. (US), and Adenium Biotech ApS (Denmark).
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: [email protected]
Website: https://www.marketresearchfuture.com
